Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Mouse, Rat, Bovine (tested or 100% immunogen sequence identity)
IHC - Paraffin (1:100 - 1:1000)
Western blot (1:500 - 1:3000)
Specificity and Use
FBXO2 antibody was raised against synthetic peptide corresponding to a region within amino acids 234 and 296 of FBXO2 (SwissProt Q9UK22). Percent identity by BLAST analysis: Human, Mouse, Rat, Bovine (100%).
IHC-paraffin: Suggested antigen retrieval using heat mediated 10 mM Citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 8.0).
PBS, pH 7.0, 10% glycerol, 0.01% Thimerosal
Keep as concentrated solution. Aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
FBXO2 Antibody, F-box gene 1 Antibody, F-box protein 2 Antibody, FBX2 Antibody, OCP1 Antibody, F-box only protein 2 Antibody, FBG1 Antibody, FBS1 Antibody, NFB42 Antibody, Organ of Corti protein 1 Antibody
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Involved in the endoplasmic reticulum-associated degradation pathway (ERAD) for misfolded lumenal proteins by recognizing and binding sugar chains on unfolded glycoproteins that are retrotranslocated into the cytosol and promoting their ubiquitination and subsequent degradation.